Cargando…

Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment

OBJECTIVE: To explore and quantify men’s preferences and willingness to pay (WTP) for attributes of medications for lower urinary tract symptoms associated with benign prostatic hyperplasia using a discrete choice experiment. SUBJECTS AND METHODS: Men in the UK aged ≥45 years with moderate-to-severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mankowski, Colette, Ikenwilo, Divine, Heidenreich, Sebastian, Ryan, Mandy, Nazir, Jameel, Newman, Cathy, Watson, Verity
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125770/
https://www.ncbi.nlm.nih.gov/pubmed/27920507
http://dx.doi.org/10.2147/PPA.S112161
_version_ 1782470016663289856
author Mankowski, Colette
Ikenwilo, Divine
Heidenreich, Sebastian
Ryan, Mandy
Nazir, Jameel
Newman, Cathy
Watson, Verity
author_facet Mankowski, Colette
Ikenwilo, Divine
Heidenreich, Sebastian
Ryan, Mandy
Nazir, Jameel
Newman, Cathy
Watson, Verity
author_sort Mankowski, Colette
collection PubMed
description OBJECTIVE: To explore and quantify men’s preferences and willingness to pay (WTP) for attributes of medications for lower urinary tract symptoms associated with benign prostatic hyperplasia using a discrete choice experiment. SUBJECTS AND METHODS: Men in the UK aged ≥45 years with moderate-to-severe lower urinary tract symptoms/benign prostatic hyperplasia (based on self-reported International Prostate Symptom Score ≥8) were recruited. An online discrete choice experiment survey was administered. Eligible men were asked to consider different medication scenarios and select their preferred medication according to seven attributes: daytime and nighttime (nocturia) urinary frequency, urinary urgency, sexual and nonsexual side effects, number of tablets/day, and cost/month. A mixed-logit model was used to estimate preferences and WTP for medication attributes. RESULTS: In all, 247 men completed the survey. Men were willing to trade-off symptom improvements and treatment side effects. Men preferred medications that reduced urinary urgency and reduced day- and nighttime urinary frequency. Men preferred medications without side effects (base-case level), but did not care about the number of tablets per day. WTP for symptomatic improvement was £25.33/month for reduced urgency (urge incontinence to mild urgency), and £6.65/month and £1.39/month for each unit reduction in night- and daytime urination frequency, respectively. The sexual and nonsexual side effects reduced WTP by up to £30.07/month. There was significant heterogeneity in preferences for most attributes, except for reduced urinary urgency from urge incontinence to mild urgency and no fluid during ejaculation (dry orgasm). CONCLUSION: To compensate for side effects, a medicine for lower urinary tract symptoms/benign prostatic hyperplasia must provide a combination of benefits, such as reduced urgency of urination plus reduced nighttime and/or reduced daytime urination.
format Online
Article
Text
id pubmed-5125770
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51257702016-12-05 Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment Mankowski, Colette Ikenwilo, Divine Heidenreich, Sebastian Ryan, Mandy Nazir, Jameel Newman, Cathy Watson, Verity Patient Prefer Adherence Original Research OBJECTIVE: To explore and quantify men’s preferences and willingness to pay (WTP) for attributes of medications for lower urinary tract symptoms associated with benign prostatic hyperplasia using a discrete choice experiment. SUBJECTS AND METHODS: Men in the UK aged ≥45 years with moderate-to-severe lower urinary tract symptoms/benign prostatic hyperplasia (based on self-reported International Prostate Symptom Score ≥8) were recruited. An online discrete choice experiment survey was administered. Eligible men were asked to consider different medication scenarios and select their preferred medication according to seven attributes: daytime and nighttime (nocturia) urinary frequency, urinary urgency, sexual and nonsexual side effects, number of tablets/day, and cost/month. A mixed-logit model was used to estimate preferences and WTP for medication attributes. RESULTS: In all, 247 men completed the survey. Men were willing to trade-off symptom improvements and treatment side effects. Men preferred medications that reduced urinary urgency and reduced day- and nighttime urinary frequency. Men preferred medications without side effects (base-case level), but did not care about the number of tablets per day. WTP for symptomatic improvement was £25.33/month for reduced urgency (urge incontinence to mild urgency), and £6.65/month and £1.39/month for each unit reduction in night- and daytime urination frequency, respectively. The sexual and nonsexual side effects reduced WTP by up to £30.07/month. There was significant heterogeneity in preferences for most attributes, except for reduced urinary urgency from urge incontinence to mild urgency and no fluid during ejaculation (dry orgasm). CONCLUSION: To compensate for side effects, a medicine for lower urinary tract symptoms/benign prostatic hyperplasia must provide a combination of benefits, such as reduced urgency of urination plus reduced nighttime and/or reduced daytime urination. Dove Medical Press 2016-11-24 /pmc/articles/PMC5125770/ /pubmed/27920507 http://dx.doi.org/10.2147/PPA.S112161 Text en © 2016 Mankowski et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mankowski, Colette
Ikenwilo, Divine
Heidenreich, Sebastian
Ryan, Mandy
Nazir, Jameel
Newman, Cathy
Watson, Verity
Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title_full Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title_fullStr Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title_full_unstemmed Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title_short Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
title_sort men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125770/
https://www.ncbi.nlm.nih.gov/pubmed/27920507
http://dx.doi.org/10.2147/PPA.S112161
work_keys_str_mv AT mankowskicolette menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT ikenwilodivine menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT heidenreichsebastian menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT ryanmandy menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT nazirjameel menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT newmancathy menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment
AT watsonverity menspreferencesforthetreatmentoflowerurinarytractsymptomsassociatedwithbenignprostatichyperplasiaadiscretechoiceexperiment